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Abstract: The pathogenic bacterium Shigella is a leading cause of diarrheal disease and mortality,
disproportionately affecting young children in low-income countries. The increasing prevalence of
antibiotic resistance in Shigella necessitates an effective vaccine, for which the bacterial lipopolysac-
charide O-antigen is the primary target. S. flexneri serotype 6 has been proposed as a multivalent
vaccine component to ensure broad protection against Shigella. We have previously explored the
conformations of S. flexneri O-antigens from serogroups Y, 2, 3, and 5 that share a common saccharide
backbone (serotype Y). Here we consider serogroup 6, which is of particular interest because of an
altered backbone repeat unit with non-stoichiometric O-acetylation, the antigenic and immunogenic
importance of which have yet to be established. Our simulations show significant conformational
changes in serogroup 6 relative to the serotype Y backbone. We further find that O-acetylation has
little effect on conformation and hence may not be essential for the antigenicity of serotype 6. This
is corroborated by an in vivo study in mice, using Generalized Modules for Membrane Antigens
(GMMA) as O-antigen delivery systems, that shows that O-acetylation does not have an impact on
the immune response elicited by the S. flexneri serotype 6 O-antigen.
Keywords: O-antigen; conformation; Shigella flexneri; molecular modeling; GMMA; O-acetylation
1. Introduction
Diarrheal disease is the eighth most common cause of death world-wide, with the
highest mortality in infants and geriatrics [1–3]. Diarrheal disease disproportionately affects
low-income regions: approximately 90% occurs in south Asia and sub-Saharan Africa [2,3].
After rotavirus, the pathogenic Gram-negative bacterium Shigella is the primary cause of
diarrheal mortality, so the increasing prevalence and antibiotic resistance of Shigella is a
cause for concern [2–8]. As a vaccine has been licensed for rotavirus, Shigella is a focus of
current vaccine development [2,6].
The O-antigen (O-Ag) on the bacterial cell surface lipopolysaccharide is the primary
target of the host immune response against Shigella and the focus of current vaccine
design [4,6,9]. On the basis of O-Ag composition, the Shigella species is divided into the
four subgroups Shigella dysenteriae, Shigella flexneri, Shigella sonnei, and Shigella boydii [6,10]
S. flexneri is the most common subgroup to cause disease (66%), followed by S. sonnei (24%),
S. dysenteriae (5%), and S. boydii (5%) [9]. For S. flexneri, five serotypes—2a, 6, 3a, 2b, and
1b—account for almost 90% of disease [6,9]. Based on analysis of structural similarities, it
has been proposed that a tetravalent vaccine containing S. flexneri serotypes 2a, 3a, 6, and
S. sonnei, would provide direct protection against 75% of S. flexneri disease, with potential
for broader coverage against non-vaccine serotypes (from shared group antigens) as high
as 90% [4,6,9].
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S. flexneri is differentiated into serogroups based on type O-factor groups (I; II; III; IV;
V; VI; VII) and further into serotypes based on group O-factors (3,4; 6; 7, 8; 9; 10; IV-1) that
are determined by phage-mediated glucosylation, phosphorylation, and O-acetylation of
the O-Ag [10,11]. Apart from serogroup 6, all of the S. flexneri serotypes share a common
backbone repeating unit (serotype Y (Sf Y), Figure 1a) [10,11] comprising four residues:
three rhamnoses (Rha) and a single N-acetylglucosamine (GlcNAc). The serogroup 6 (Sf 6)
backbone repeating unit consists of two Rha residues, a galacturonic acid (GalA), and
an N-acetylgalactosamine (GalNAc) residue (Figure 1c) [10,11] and is acidic due to the
presence of the charged GalA residue.
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O-factor 9 epitope. In clinical trials, vaccination with an O-acetylated Sf 2a conjugate in 
humans (children and adults) induced protective antibodies against Sf 6 [18]. The reverse 
was also seen in two cases where children (unvaccinated with Sf 2a) who developed Sf 6 
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repeating units of S. flexneri modelled in this work: (a) serotype Y (Sf Y), (b) non-biological serotype 6n (Sf 6n) with Gal
instead of GalA, (c) serotype 6 (Sf 6), (d) serotype 6 with 100% O-acetylation at O3 of RhaIII (Sf 6-3Ac), and (e) serotype 6
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Sf 6 has only one structural modification characterized: a phage-mediated, random,
and non-stoichiometric O3/O4 acetylation of RhaIII (residue A, Figure 1d,e) [10,14]. Modifi-
cation on O3 confers group O-factor 9 onto Sf 6 and is also observed in serotypes 1b, 2a, 5a,
7a, Y1, and Y2 [10,15]. An important question in the context of the O-Ag as a vaccine target
is whether O-acetylation is important for antigenicity and immunogenicity; in the case
of S. flexneri serotype 2a (Sf 2a), O-factor 9 has been shown to not add to broad antibody
recognition [16].
When it is present, cross-protection between antigens allows for reduction of the
number of costly vaccine components [17]. Cross-reactivity between serotypes is expected
when a shared epitope is present and, although Sf 6 has a different backbone to the non-
serotype 6 backbones, cross reactivity between Sf 2a and Sf 6 is expected, due to the shared
O-factor 9 epitope. In clinical trials, vaccination with an O-acetylated Sf 2a conjugate in
humans (children and adults) induced protective antibodies against Sf 6 [18]. The reverse
was also seen in two cases where children (unvaccinated with Sf 2a) who developed Sf 6
disease subsequently developed protective antibodies against Sf 2a [18]. However, data
from mouse models showed no cross-reactivity between Sf 6 and Sf 2a [18].
Molecular modeling of antigen conformations can provide insight into the likelihood
of cross-protection between S. flexneri O-Ags [15,19]. We have previously modelled the
conformations of S. flexneri serogroup Y, 2, 3, and 5 O-antigens [15,19]. The molecular
dynamics simulations revealed that S. flexneri serotypes are highly flexible, with a wide
distribution of conformations. Substitutions of the backbone residues (glucosylation and/or
O-acetylation) were found to limit the flexibility and distribution of conformations to
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varying degrees and we proposed three guiding heuristics to describe and predict the effect
of substitutions [19]. Particularly of relevance to Sf 6 is that we found that substitution with
O-factor 9 restricts the O-Ags to predominantly helical conformations. Conformational
differences highlighted by this work support the inclusion of both serotypes 2a and 3a in a
potential vaccine. We now focus on Sf 6 (type O-factor VI; group O-factor 9), the second
most prevalent cause of S. flexneri disease in low- and middle-income countries [9].
In this work we performed molecular dynamics (MD) simulations of the five structures
listed in Figure 1: the common Sf Y backbone (Figure 1a); a neutral (non-biological)
serotype 6n in which GalA is replaced with Gal (Sf 6n; Figure 1b); Sf 6 (Figure 1c); as
well as Sf 6 with 100% O-acetylation at either O3 of RhaIII (Sf 6-3Ac, Figure 1d) or O4
of RhaIII (Sf 6-4Ac, Figure 1e). The specific aims of this study are to compare: (a) the
conformation and dynamics of the unique Sf 6 backbone with the common Sf Y backbone;
(b) the conformation of Sf 6 with the neutral Sf 6n, to establish the effect of charge on
conformation; and (c) the effect of O-acetylation at O3 or O4 of RhaIII (residue A) on Sf 6
conformation.
To corroborate our modeling results on O-acetylation, we performed immunological
studies in mice with the aim of understanding whether the presence of the O-acetyl group
has an impact on S. flexneri 6 O-Ag immunogenicity. We genetically manipulated wild type
Sf 6 by deleting the oacC gene which codes for the O-acetyltransferase C enzyme that is
responsible for the O-acetylation of the O-Ag on RhaIII (residue A). Mice were then immu-
nized using Sf 6 Generalized Modules for Membrane Antigens (GMMA) [20] (a proposed
alternative delivery system for Shigella O-Ags [21,22]) obtained from either the wild-type
or the oacC knock-out S. flexneri 6 strains [23] and the immune responses compared.
2. Materials and Methods
2.1. Molecular Simulations
We used our established systematic approach to the modeling of polysaccharides,
as follows [19,24]. To identify the preferred orientation of each glycosidic linkage, two-
dimensional ϕ, ψ potential mean force (PMF) calculations were performed for the glyco-
sidic linkages of all the disaccharide fragments of the O-Ag repeating units. The glycosidic
linkage orientations are generally defined by two dihedral angles, ϕ = H1-C1-O1-Cx’ and
ψ = C1-O1-Cx’-Hx’, which are equivalent ϕ and ψ in IUPAC nomenclature [15].
The preferred glycosidic linkage orientations identified by the PMFs were then used
to build three repeating unit (3 RU) O-Ag chains for initial Molecular Dynamics (MD) sim-
ulations in aqueous solution (data not shown), which were then extended to six repeating
unit (6 RU) chains. Chain length is an important consideration when modeling O-Ags, as a
short chain may have insufficient molecular flexibility while long chains become extremely
time consuming and too computationally expensive to model. S. flexneri exhibits a range of
O-Ag chain lengths, however, 3RU is considered sufficient to represent O-Ag conformation
(based on our previous work with S. flexneri and studies in mice) [15,19,20,25,26]. Further-
more, antibodies have been shown to only bind small fragments of the O-Ag between one
and seven residues in length corresponding to 1–2 RU in the case of S. flexneri [27].
Following initial system equilibration, molecular dynamics runs of 1–2 µs were per-
formed and data analyses were performed on these production runs.
2.1.1. PMF Calculations
Disaccharide structures were built using CarbBuilder and visualized with Visual
Molecular Dynamics (VMD) software [28–30]. PMF calculations were performed using the
Metadynamics package incorporated into the Nanoscale Molecular Dynamics (NAMD)
software [31]. The ϕ and ψ dihedrals used as collective variables to establish preferred
conformations for rotation about the ϕ and ψ dihedrals of the glycosidic linkages in the
disaccharide units.
For all neutral disaccharides, calculations were performed in vacuum (gas phase). For
all charged disaccharides, calculations were performed in solution, using the TIP3P [32]
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model of water with a sodium counter-ion to ensure system neutrality (a requirement
for the calculations of electrostatic interactions to converge). Systems were solvated and
ionized using VMD’s built in solvation and ionization tools.
Each disaccharide system was run at 300 K for 1000 ns (vacuum simulations) or until
the biasing energy reached at least 10 kcal.mol−1 (solution simulations). Once the runs
were complete, internal scripts were used to extract global and local minimum energies
and to generate contour plots of ϕ versus ψ.
2.1.2. Molecular Dynamics
Simulations were run using NAMD (version 2.13) with CUDA extensions for utilizing
graphics processors for parallel computing [33]. The CHARMM36 additive force field was
chosen for the simulations [34,35].
The data for Sf Y from our previous work [15] was extended by 1000 ns and included
in this study. Starting structures of the Sf 6 O-Ags (Figure 1) were built with CarbBuilder
using the global minima for the glycosidic linkages determined from the PMF calculations.
The starting structures were subsequently minimized using NAMD for 10,000 steps at
310 K.
Minimized structures were solvated in cubic TIP3P [32] water boxes of 90 Å per
side. The charged Sf 6, Sf 6-3Ac and Sf 6-4Ac systems underwent an ionization step to
add six sodium (Na+) counter ions to neutralize the system. Initial minimization and
heating protocols comprised 5 K incremental temperature reassignments beginning at
10 K up to 310 K with 5000 steps of NAMD minimization and 2000 steps of MD at each
temperature reassignment.
Periodic boundary conditions equivalent to the cubic box size were employed for the
solvated simulation with wrapping on. Long range electrostatics were implemented with
Particle Mesh Ewald summation (PME) on a 90 Å grid size [36]. Of the pairs, 1–3 were
excluded from non-bonded interactions, 1–4 interactions were scaled by a factor of 1, and a
dielectric constant of 1 was used for the system. Smoothing functions were applied to both
the electrostatics and van der Waals forces with switching and cut-off distances of 15 Å and
12 Å respectively.
A Leap-Frog Verlet integrator was used to integrate the equations of motion over
a step size of 1 fs. A distance of 18 Å was used as the cut-off for inclusion in the pair
list for calculation of non-bonded forces. The short-range non-bonded interactions were
calculated every 1 fs, full electrostatics calculations were performed every 2 fs, and atoms
were reassigned every 10 fs [37].
Simulations were sampled under isothermal-isobaric (nPT) ensemble. Langevin
dynamics were used to control the temperature with a damping coefficient of 5/ps. Nosé-
Hoover Langevin piston dynamics were used as a barostat to maintain a target pressure of
1 atm. Variable system volume was used with a piston period of 100 fs and decay of 50 fs.
Post equilibration (200 ns), simulations underwent production runs of 1800 ns for Sf Y and
Sf 6, 800 ns for Sf 6n, and 900 ns Sf 6-3Ac and Sf 6-4Ac as different simulation lengths were
required for the different models to appear converged.
2.1.3. Simulation Convergence
We addressed the convergence using the method of block standard averaging, applied
to two measurables: molecular end-to-end distance and radius of gyration (see Supple-
mentary Figure S1), as previously described, and implemented the method using in-house
Python scripts [19,38].
For all serotypes modeled, the blocked standard error (BSE) can be seen to have
reached plateaus. The simulation lengths were large multiples of the correlation times (Sf Y,
50 ns; Sf 6n, 24 ns; Sf 6, 6 ns; Sf 6-3Ac, 11 ns; Sf 6-4Ac,18 ns) and numbers of independent
samples (Sf Y, 40; Sf 6n, 83; Sf 6, 180; Sf 6-3Ac, 102; Sf 6-4Ac, 60) were >>1. Furthermore,
the equilibration time of 200 ns was >> the correlation time. Thus, the simulations appear
converged and 200 ns equilibration is sufficient. For Sf Y and Sf 6, longer simulation times
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were required for convergence (both 2000 ns) than for Sf 6n (1000 ns), Sf 6-3Ac (1100 ns),
and Sf 6-4Ac (1100 ns).
2.1.4. Data Analysis
Output trajectories were extracted every 25 ps and analyzed at 250 ps intervals.
Inter-atomic distances and dihedral angles were measured using VMD’s Tk console and
graphical user interface (GUI) with data analyses performed using in-house Python scripts
and plots generated using Matplotlib [39].
The end-to-end distance, r, was measured from C2 of RhaII (residue B) at the non-
reducing end, to C1 of RhaI/GalA (residue C) at the reducing end, thus excluding the
highly flexible terminal residues.
The dihedral angles for each glycosidic linkage were measured as a combination of
the dihedrals from the central repeating units, 3 and 4, thus providing a sample of the most
central angles.
Molecular conformations were visualized using VMD and clustering of production
run trajectories were performed using the WMC PhysBio GUI for VMD’s built-in cluster
command [40]. Prior to clustering, the molecules were aligned on the ring and linkage
atoms of the least flexible central repeating unit, RU 3. Clustering was performed on the
ring and linkage atoms in RUs 2, 3, 4, and 5, avoiding the highly flexible terminal repeating
units 1 and 6. A cut-off of 5.5 Å was set and clusters < 6% were discarded.
Hydrophilic/hydrophobic regions of the molecular surface were analyzed using
VMD’s built in “measure sasa” command. The solvent accessible surface area (sasa) anal-
ysis was performed by probing first hydrophilic regions (comprising hydroxyl groups,
carbonyl groups, amine groups, ring oxygens, and linkage oxygens) and then hydropho-
bic/neutral regions (comprising methyl groups, CH2 groups, ring carbons, and ring pro-
tons) of the molecule using a van der Waal’s radius of 1.4 Å-analogous to that of water. The
ratio of hydrophilic to hydrophobic/neutral regions was then calculated to determine the
percentage hydrophilic surface area available for potential antibody binding.
When necessary, carbohydrate rings were visualized using the PaperChain visualiza-
tion algorithm and the hydrophilic and hydrophobic surfaces were visualized using the
Quicksurf visualization algorithm [41,42].
2.2. Immunological Studies
We compared the immune responses in vaccinated mice and their functional activity
against both Sf 6 and de-O-acetylated Sf 6 strains. We genetically manipulated wild type
Sf 6 by deleting the oacC gene which codes for the O-acetyltransferase C enzyme that
is responsible for the O-acetylation of the O-Ag on RhaIII (residue A). Mice were then
immunized using Sf 6 GMMA [20] obtained from either the wild-type or the oacC knock-
out S. flexneri 6 strains [23]. GMMA are Outer Membrane Vesicles (OMV) naturally released
from Gram-negative bacteria mutated to increase OMV yield, proposed as an alternative
delivery system for Shigella O-Ags [21,22].
2.2.1. Bacterial Strains, Mutant Generation and Growth Conditions
A S. flexneri 6 wild type strain was obtained from the Wellcome Trust Sanger Institute
and Public Health England [43]. Strain Sf6_Sh10.8537 was selected for the generation of
deletion mutants. To generate the mutants, the kanamycin resistance gene aph was used to
replace the tolR and the oacC genes. The resistance cassette replacement constructs were am-
plified from the pKD4 vector using the following primers: Fw ATGTTTGAAATTGATAGC-
CTATTATTAATAACATCCGTGATAATCTTGTCGTGTAGGCTGGAGCTGCTTC and Rv
GGTTTGTTTTGTTATATTAATGAAAGGTAGTTCAATTAATTTAAATGTTACATATGAAT
ATCCTCCTTAG. PCR products were used to transform recombination-prone S. flexneri 6
recipient cells carrying pKD46 as described previously [44]. The oacC gene was also deleted
in a non-∆tolR background (not overblebbling) for use as a target strain in SBA experiments.
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All bacterial strains were grown at 30 ◦C in liquid Luria–Bertani (LB) medium in a
rotary shaker for 16 h. For GMMA production, overnight cultures were diluted in HTMC
medium (15 g/L glycerol, 30 g/L yeast extract, 0.5 g/L MgSO4, 5 g/L KH2PO4, and 20 g/L
K2HPO4) to an optical density at 600 nm (OD600) of 0.3 and grown at 30 ◦C in a rotary
shaker for 8 h using baffled flasks with a liquid to air volume ratio of 1:5.
2.2.2. GMMA Production and Characterization
After growth, bacteria were pelleted through centrifugation at 5000× g for 45 min
at 4 ◦C. Cell-free supernatants were ultracentrifuged at 175,000× g for 2 h at 4 ◦C; the
resulting pellet, containing GMMA, was washed with phosphate-buffered saline (PBS),
further ultra-centrifuged at 175,000× g for 2 h at 4 ◦C and finally resuspended in PBS.
GMMA purity was assessed by HPLC–SEC analysis [45]; total protein content was
estimated by micro BCA (Thermo Scientific, Waltham, MA, USA); O-Ag sugar content
was quantified by determination of methyl pentoses (6-deoxyhexoses) with the Dische
colorimetric method [46].
O-Ag extraction and purification from GMMA was performed as previously de-
scribed [45].
Nuclear magnetic resonance (NMR) spectroscopy was used to confirm O-Ag identity
and to calculate the degree of O-acetylation [11]. All NMR spectra were acquired at 50 ◦C
with an AEON AVANCE III 600 MHz spectrometer (Bruker, Billerica, MA, USA) equipped
with a high-precision temperature controller using a 5 mm QCI CryoProbe as previously
described [20].
2.2.3. Immunogenicity Studies in Mice
Animal studies were performed at the GSK Animal Care Facility under the animal
project 526/2020-PR 26/05/2020, approved by the Italian Ministry of Health. All animal
studies were ethically reviewed and carried out in accordance with European Directive
2010/63/EEC and the GSK policy on the Care, Welfare and Treatment of Animals. Five-
week-old female wild-type mice were immunized intraperitoneally with 200 µL of vaccine
at days 0 and 28. Sera were collected at day 42. Different O-Ag doses were tested in the
range 0.005–0.5 µg.
Individual mouse sera were tested for anti-O-Ag total IgG by enzyme-linked im-
munosorbent assay (ELISA), as previously described [47]. S. flexneri 6 Group 4 Capsule
(G4C) [20], sharing the same O-Ag RU, at a concentration of 5 µg/mL in carbonate buffer
pH 9.6, was used as a coating antigen. Single sera were tested against both a wild-type
and an oacC knock-out S. flexneri 6 strain in a serum bactericidal assay (SBA) based on
luminescent readout as described previously [20,48].
Results of the assay were expressed as the IC50: the reciprocal serum dilution that
produced a 50% reduction of luminescence, which corresponds to 50% growth inhibition
of the bacteria present in the assay [49,50]. GraphPad Prism 7 software (GraphPad Softare,
San Diego, California) was used for curve fitting and IC50 determination. Titers below the
minimum measurable signal were assigned a titer of 50, corresponding to half of the first
dilution of sera tested.
Statistical analysis was performed using GraphPad Prism 7. Dose-response rela-
tionships were evaluated through Spearman’s rank correlation. The parallelism of dose-
response curves was assessed by the parallel line method: when the slopes of the curves
for O-Ac and non-OAc O-Ags obtained by log-transforming ELISA or SBA results vs. log
transformed antigen doses were not significantly different from each other, comparison of
the Y-intercepts was performed.
3. Results
Using the simulation data for SF Y, Sf 6n, Sf 6 and the O-acetylated Sf 6-3Ac and Sf
6-4Ac, we first compare the chain flexibilities of the O-Ags, then consider the molecular
conformations, the characteristics of the molecular surface and finally contrast the minimal
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binding epitopes. In light of these results, we then consider the effect of O-acetylation on
Sf 6 immunogenicity in mice.
3.1. Chain Extension and Flexibility
Time series plots of the molecular end-to-end distance, r, over the course of the MD
simulations provide a simple comparison of the molecular flexibility and chain extension of
the O-Ags. We defined r (illustrated in Figure 2a) as the distance from C2 of RhaII (residue
B) in RU 1 to C1 of RhaI (residue C) in RU 6 (for Sf Y), or the equivalent C1 of GalA in RU 6
(for Sf 6′s). Comparison of the r time series plots (Figure 2 left column) and corresponding
histograms (Figure 2 right column) reveals significant differences between the Sf Y and Sf 6
O-Ags. Sf Y (Figure 2b) is the most flexible, with the greatest variance (σ = 15) and range
(10 Å to 70 Å) of r. Further, r has a bimodal distribution for Sf Y (with peaks at 25 Å and
52 Å) that is markedly different to the unimodal, left skewed distributions of the Sf 6′s:
the Sf Y backbone has a significant population of compact conformations that is absent in
the Sf 6′s. In contrast, the distribution of r across the four variations of Sf 6 is remarkably
similar: the graphs show that the chains are predominantly extended and that the addition
of charge or O-acetylation to the Sf 6 backbone has only a minor effect on the O-Ag chain
extension and flexibility. The uncharged Sf 6n (Figure 2c) is the most flexible Sf 6 O-Ag
with the largest range of r (15 Å to 70 Å, σ = 12). Sf 6 (Figure 2d) has a similar r distribution
(10 Å to 70 Å, σ = 11), while the O-acetylated Sf 6-3Ac (Figure 2e) and Sf 6-4Ac (Figure 2f)
are the most extended chains and show some reduction in flexibility (σ = 10). Overall,
flexibility of the O-Ags decreases in the order Sf Y >> Sf 6n > Sf 6 > Sf 6-4Ac > Sf 6-3Ac.
3.2. Molecular Conformations
Figure 3 provides a comparison of the dominant chain conformations for Sf Y and
the Sf 6 O-Ag, as determined by cluster analysis. While the wide range of conformations
demonstrate that all the O-Ags are very flexible and mostly extended, the Sf Y backbone
adopts compact conformations (Figure 3a: Y-2, Y-4, Y-6) that do not occur in any of the
Sf 6′s (Figure 3b–e). Further, while Sf Y moves between extended and collapsed, helical,
and non-helical conformations, the Sf 6 chains adopt the same helical structure in different
stages of elongation or compression. Furthermore, the Sf Y helices (Figure 3a: Y-1) are
right-handed, whereas the Sf 6′s helices are all left-handed. We investigated the structural
basis of the change in handedness of the helix by building 6 repeating unit static structures
of Sf Y with our CarbBuilder software, each with one of the structural modifications seen
in serotype 6′s backbone (supplementary Figure S2). Of these static structures, only one
change, the replacement of the αLRha(1→3)αLRha linkage with the αLRha(1→4)βDGalA
linkage (the BC linkage), caused a shift from a right handed helix to left handed, indicating
that the change in this linkage position and configuration causes the change in handedness
of the helix. This is also apparent in a comparison of heatmaps of the ϕ and ψ dihedral
angles (Figure S3 and Table S1) of Sf Y and Sf 6. The occupancies of the AB and DA linkages
are mostly unchanged, whereas the shape and location of the BC linkage is very different
in Sf 6 with a small change also seen in the adjacent CD linkage.
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Figure 2. End-to-end distance, r, is defined as shown in (a) with end-to-end distance time series as
well as histograms shown for O-Ags (b) Sf Y, (c) Sf 6n, (d) Sf 6, (e) Sf 6-3Ac, and (f) Sf 6-4Ac. The
standard deviation of each histogram, σ, is shown.
Substitutions to the Sf 6 backbone have some small conformational effects, as follows.
The addition of charge on Gal slightly elongates the helices: compa e the primary confor-
mation of the neutral Sf 6 O-Ag (Figure 3b, 6n-1) w th charged Sf 6 (Figure 3c, 6-1).
The greater steric hindrance of the charged GalA monosaccharide versus the neutr l Gal is
likely the reason f r the greater extension observed in the charged Sf 6 O-Ag, also account-
ing for th neutral Sf 6n being more flexibl than the charge Sf 6 as seen above. However,
O-acetylation does not have a large conform ti nal impact. T primary onformations of
Sf 6-3Ac (Figure 3d) and Sf 6-4Ac (Figure 3e) are very similar extended helices–compare
6_3Ac-1, 6_4Ac-1 with 6-1. Of interest is that all the backbone substitutions-the charged
carboxylic acid group on GalA and the O-acetyl groups-are situated on the outside of the
helix where they may be easily accessible for antibody binding. In addition, the O3 acetyl
group interacts more with the chain backbone than the O4 acetyl, due to its close proximity
to the linkage position at C2.
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the conformational clusters (excluding the initial 200 ns of equilibration) are shown as percentages
with clusters less than 6% not shown. The color scheme is as follows: blue for Glc and GlcNAc;
purple for Rha; yellow for Gal, GalA, and GalNAc; green for the COOH group of GalA; red for the
O-acetyl groups.
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3.3. Molecular Surface
While similar in conformation, the O-Ags differ in charges and substituents. Compar-
ison of the hydrophilic and hydrophobic regions of the molecular surface in the O-Ags
highlights differences between the O-Ags that may affect antibody binding.
Time series and histograms of the hydrophilic surface area of each frame of the
trajectory are plotted in Figure 4, where hydrophilic surface area refers to the percentage
of the surface area that is hydrophilic relative to total solvent accessible surface area. Sf Y
(Figure 4a) is markedly more hydrophobic than Sf 6n (Figure 4b) and Sf 6 (Figure 4c),
and also shows a greater variation in surface hydrophilicity. This is because the extended
conformations of the backbone (Figure 4f) expose more hydrophobic patches (blue) than
the collapsed conformations of Sf Y (Figure 4g). The hydrophobicity of Sf Y relative to
the Sf 6′s can be rationalized by considering the surfaces of the individual constituent
monosaccharides of the backbone (Figure S4)–Gal is markedly more hydrophilic than Glc
or Rha. Overall, the hydrophilicity of the exposed O-Ag surface decreases in the order:
Sf 6 (55%) > Sf 6n (52%) > Sf 6-3Ac (51%) > Sf 6-4Ac (50%) > Sf Y (46%).




Figure 4. Time series and histogram plots of relative % hydrophilic surface area for O-Ags: (a) Sf 
Y, (b) Sf 6n, (c) Sf 6, (d) Sf 6-3Ac, (e) Sf 6-4Ac. VMD Quicksurf representation of the hydrophilic 
(blue) and combined neutral/hydrophobic (pink) surfaces of the O-antigens are shown in (f) or-
dered from highest (Sf 6) to lowest (Sf Y) % hydrophilic surface. (g) VMD Quicksurf representation 
of a collapsed Sf Y conformation from around. Note that for Sf Y and Sf 6, longer simulation times 
were required to reach convergence (both 2000 ns) than for Sf 6n (1000 ns), Sf 6-3Ac (1100 ns), and 
Sf 6-4Ac (1100 ns). 
3.4. Minimal Binding Epitope 
As antibodies bind to O-Ag regions comprising one to seven residues [27], it is useful 
to consider the differences in the 6 RU O-Ag’s on this length scale. Figure 5 compares the 
main conformation and the surface hydrophilicity of a central four residue (BCDA) seg-
ment across the Sf Y and Sf 6 O-Ags. It is clear that Sf Y (Figure 5a) has a very different 
conformation to the SF 6′s. The Sf Y repeting unit is more condensed, residue B is rotated 
180°, and the residue B methyl (Me) group interacts with the N-Acetyl on residue D. The 
surface representations for Sf Y also show smaller regions of hydrophilicity (blue) com-
pared to the Sf 6′s 
Figure 4. Time series and histogram plots of relative % hydrophilic surface area for O-Ags: (a) Sf Y, (b) Sf 6n, (c) Sf 6, (d) Sf
6-3Ac, (e) Sf 6-4Ac. VMD Quicksurf representation of the hydrophilic (blue) and combined neutral/hydrophobic (pink)
surfaces of the O-antigens are shown in (f) ordered from highest (Sf 6) to lowest (Sf Y) % hydrophilic surface. (g) VMD
Quicksurf representation of a collapsed Sf Y conformation from around. Note that for Sf Y and Sf 6, longer simulation times
were required to reach convergence (both 2000 ns) than for Sf 6n (1000 ns), Sf 6-3Ac (1100 ns), and Sf 6-4Ac (1100 ns).
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Unsurprisingly, the charged Sf 6 is more hydrophilic than the neutral O-Ag (Sf 6n).
It is also clear that O-acetylation decreases the hydrophilicity of the chain: with Sf 6-3Ac
(Figure 4d) showing a smaller decrease (4%) than Sf 6-4Ac (5%, Figure 4e) which has the
O-methyl more exposed on the chain.
3.4. Minimal Binding Epitope
As antibodies bind to O-Ag regions comprising one to seven residues [27], it is useful
to consider the differences in the 6 RU O-Ag’s on this length scale. Figure 5 compares
the main conformation and the surface hydrophilicity of a central four residue (BCDA)
segment across the Sf Y and Sf 6 O-Ags. It is clear that Sf Y (Figure 5a) has a very different
conformation to the SF 6′s. The Sf Y repeting unit is more condensed, residue B is rotated
180◦, and the residue B methyl (Me) group interacts with the N-Acetyl on residue D.
The surface representations for Sf Y also show smaller regions of hydrophilicity (blue)
compared to the Sf 6′s




Figure 5. Close up of BCDA residues of RU3/4 in the licorice/paperchain/VDW and Quicksurf rep-
resentations of the primary clusters of: (a) Sf Y, (b) Sf 6n, (c) Sf 6, (d) Sf 6-3Ac, and (e) Sf 6-4Ac O-
antigens. The licorice/paperchain/VDW colors: purple- Rha; dark blue—Glc; yellow—Gal; green—
COOH; red—O-acetyl; orange—Me; and cyan—electron withdrawing portion of NAc. The Quick-
surf colors: blue—hydrophilic surface, pink—hydrophobic & neutral surface. 
The Sf 6′s (Figure 5b–d) all have similar conformations of the central BCD fragment; 
the methyl (Me) on residue B interacts with the hydroxyl (OH) or carboxylic acid (COOH) 
group on C6 of residue C. The substitutions on the Sf 6 backbone do not affect the orien-
tation of this fragment significantly, but they do affect the DA fragment and the binding 
surface. Relative to Sf 6 (Figure 5c), O-acetylation at O3 in Sf 6-3Ac (Figure 5d) or O4 in Sf 
6-4Ac (Figure 5e) results in a disruption of the hydrophilic regions (blue) of residue A (O3 
and O4 region) and residue D (NAc region). For the residue A region, the substituted 
position (O3 or O4) becomes hydrophobic, reducing the size of the local hydrophilic re-
gion and, in the case of Sf 6-4Ac, shifting upwards due to a change in orientation of the O-
acetyl to reduce steric hindrance. The residue D region (associated with NAc) shifts to-
wards residue A in Sf 6-3Ac due to NAc–O3Ac interactions and in Sf 6-4Ac, merges with 
the O3 hydrophilic region. 
Overall, the differences between Sf Y and Sf 6 orientations and hydrophilic surfaces 
indicate the likely antigen binding sites are significantly different. Furthermore, this four-
residue region is very similar in the Sf 6′s, suggesting that that O-acetylation does not have 
a significant effect on the potential antigen binding site, and hence immunogenicity, of the 
Sf 6 O-Ag. 
Figure 5. Close up of BCDA residues of RU3/4 in the licorice/paperchain/VDW and Quicksurf
representations of the primary clusters of: (a) Sf Y, (b) Sf 6n, (c) Sf 6, (d) Sf 6-3Ac, and (e) Sf 6-4Ac
O-antigens. The licorice/paperchain/VDW colors: purple- Rha; dark blue—Glc; yellow—Gal; green—
COOH; red—O-acetyl; orange—Me; and cyan—electron withdrawing portion of NAc. The Quicksurf
colors: blue—hydrophilic surface, pink—hydrophobic & neutral surface.
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The Sf 6′s (Figure 5b–d) all have similar conformations of the central BCD fragment;
the methyl (Me) on residue B interacts with the hydroxyl (OH) or carboxylic acid (COOH)
group on C6 of residue C. The substitutions on the Sf 6 backbone do not affect the orien-
tation of this fragment significantly, but they do affect the DA fragment and the binding
surface. Relative to Sf 6 (Figure 5c), O-acetylation at O3 in Sf 6-3Ac (Figure 5d) or O4 in
Sf 6-4Ac (Figure 5e) results in a disruption of the hydrophilic regions (blue) of residue A
(O3 and O4 region) and residue D (NAc region). For the residue A region, the substituted
position (O3 or O4) becomes hydrophobic, reducing the size of the local hydrophilic region
and, in the case of Sf 6-4Ac, shifting upwards due to a change in orientation of the O-acetyl
to reduce steric hindrance. The residue D region (associated with NAc) shifts towards
residue A in Sf 6-3Ac due to NAc–O3Ac interactions and in Sf 6-4Ac, merges with the O3
hydrophilic region.
Overall, the differences between Sf Y and Sf 6 orientations and hydrophilic surfaces
indicate the likely antigen binding sites are significantly different. Furthermore, this four-
residue region is very similar in the Sf 6′s, suggesting that that O-acetylation does not have
a significant effect on the potential antigen binding site, and hence immunogenicity, of the
Sf 6 O-Ag.
3.5. The Impact of O-Acetylation on the Immunogenicity of Sf 6 GMMA in Mice
To investigate the impact of O-acetylation on the immune response induced by the Sf
6 O-Ags (and verify the predictions made by modeling) the GMMA-producing strain Sf 6
Sh10.8537 ∆tolR was further mutated to abolish RhaIII O-acetylation by removing the oacC
gene-coding for the O-acyltransferase C enzyme-responsible for the backbone modification
that confers the presence of O-factor 9. Both GMMA we free of soluble proteins and DNA
as detected by HPLC-SEC analysis. The O-Ag to protein weight ratio was 0.4 in the wild
type GMMA and 0.23 in ∆oacC GMMA. The O-Ag chains on both GMMA had three main
populations at average sizes of 174 kDa (G4C), 22 kDa and 1.7 kDa [20], respectively. 1H
NMR analysis of the O-Ag extracted from the ∆oacC GMMA confirmed the absence of
O-acetylation on RhaIII, while the O-Ag from the wild type GMMA was O-acetylated at
positions 3 and 4 of RhaIII (73.3% and 17.9%, respectively), as shown in Figure S5.
The characterization of the resulting GMMA by 1H NMR analysis (Figure S5) con-
firmed the absence of O-acetylation on RhaIII. Moreover, the % O-acetylation at positions 3
and 4 of RhaIII of the native O-Ag were calculated as 73.26% and 17.95%, respectively.
The immunogenicity of GMMA displaying O-Ag with or without O-acetylation on
RhaIII was tested in a dose ranging study in mice, comparing GMMA constructs at the
same O-Ag dose. Analysis of sera collected two weeks after the second immunization at
day 28 (day 42) showed that wild type and ∆oacC GMMA did not induce significantly
different anti-O-Ag total IgG response in the dose range tested (Figure 6a).
SBA analysis against both wild type and ∆oacC S. flexneri serotype 6 strains con-
firmed the results obtained in ELISA, indicating additionally, that the functionality of the
antibodies induced was not affected by O-Ag O-acetylation (Figure 6b).
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Figure 6. Immunogenicity in mice of S. flexneri 6 (Sf) GMMA differing in O-Ag O-acetylation on RhaIII. Eight CD1 mice per
group were immunized intraperitoneally with three doses of O-Ag (0.005, 0.05, 0.5 µg). S. flexneri 6 Group 4 Capsule (G4C),
encompassing the same RU of the O-Ag, was used as th ELISA coating antigen. (a) Summary graph of anti-G4C specific
IgG geometric mean units (bars) and individual antibody levels (dots) on the left; s atistical comparison of the resulting
dose response curves on the right; (b) Summary graphs of SBA IC50 titers against S. flexneri 6 wild type (on the left) and
∆oacC (on the right) strains. ELISA and SBA data were analyzed using the parallel line approach. Each curve represents
log-transformed doses on the abscissa and the log-transformed ELISA units or SBA titers on the ordinate. The parallelism of
the lines was tested by comparison of the slopes, which resulted in no significant differences. Subsequently, the Y-intercept
of the curves were compared, and the p-values are reported in the graphs.
4. Discussion
Our simulations show that the Sf Y and Sf 6 O-Ags are very flexible, in common with
serogroups 2, 3, and 5 modeled previously. However, while Sf Y adopts both elongated
and collapsed structures, including right-handed helices, the Sf 6 O-Ags are predominantly
in an extended left-handed helical conformation. This conformational change is a result
of the change of the BC linkage from a flexible equatorial configuration in Sf Y to a more
constrained axial configuration in Sf 6. Due the significant conformational differences
between the Sf Y backbone and Sf 6, cross-protection between Sf 6 and Sf Y is not expected
to occur.
O-acetylation is known to alter carbohydrate chemical and physical properties, such
as molecular conformation and hydrophobicity, thereby affecting the antigenicity and
immunogenicity of antigens of relevance for vaccine design [51]. Recent reviews on Shigella
vaccine development [26] and the role of O-acetylation [51] confirm its contribution to the
functional immune response for some licensed bacterial polysaccharide-based vaccines
(Salmonella typhi Vi and Neisseria meningitidis serogroup A), but not for others, indicating
that the importance of O-acetylation must be established on a case-to-case basis. For
Shigella, O-acetylation is recognized as a source of additional antigenic diversity and has
been characterized by group O-factors [23]. In the case of Sf 6, the presence of RhaIII3/4Ac
introduces group O-factor 9 and three subtypes have been recognized on the basis of levels
of O-acetylation (I and II) and its absence (III) [51]. Further, the presence of an O-acetylated
Vaccines 2021, 9, 432 14 of 16
rhamnobiose (αLRhaIII3/4Ac(1→3)αLRhaII) has been suggested as the structural basis for
the observed cross-reactivity between Sf 2a and SF6 [18,51].
Our simulations show that O-acetylation of Sf 6 at O3 or O4 of RhaIII (residue A) does
not alter the backbone conformation significantly, suggesting that O-acetylation may not
be essential for antigenicity. However, O-acetylation results in a significant decrease in
the hydrophilicity of the O-Ag in Sf 6 compared to de-O-acetylated Sf 6 based on solvent
accessible surface area calculations. This may affect the binding affinity of Sf 6 compared
to de-O-acetylated Sf 6, however, the biological significance of this parameter is yet to
be established.
Indeed, our comparison of Sf 6 O-Ags with and without O-acetylation on RhaIII
(delivered on GMMA) in mice confirmed that O-acetylation does not play a major role in
the ability of the O-Ag to induce antibodies able to recognize the O-acetylated RU and
to kill O-acetylated or de-O-acetylated S. flexneri 6 bacteria. The results obtained in vivo
corroborate the modeling analysis, showing no impact of O-acetylation on immunogenicity.
This is in line with the marginal difference observed in the O-Ag conformation. These
results are also in agreement with our studies on CRM197 glycoconjugates [20].
Further validation of the importance of the O-acetylation and cross reactivity of
S. flexneri serotype 6 in other animal models (and preferably humans) is necessary to
definitively confirm the role of O-acetylation in immunogenicity and provide insight into
appropriate, representative animal models for Shigella sp vaccine development.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9050432/s1, Figure S1: Blocked standard error calculations for determining the extent
of simulation convergence, Figure S2: Static structures for establishing the origin of the handedness
of the S. flexneri serotype 6 backbone, Figure S3: Heat map representation of scatter plots for the
phi (ϕ), psi (ψ) dihedral angles of glycosidic linkages of S. flexneri serotype Y and 6 backbones,
Table S1: Tabulation of primary and secondary occupied dihedral angles of glycosidic linkages for
the modelled O-antigens, Figure S4: Hydrophilic/hydrophobic surface visualization of S. flexneri
serotype Y and 6 constituent monosaccharides, Figure S5: Diagnostic 1H NMR spectra of S. flexneri 6
O-Ags extracted from GMMA produced by the wild type and ∆oacC mutant strains.
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